Vyant Bio, Inc. (OTCMKTS:VYNT – Get Free Report) shares rose 7.8% during trading on Tuesday . The stock traded as high as $0.20 and last traded at $0.19. Approximately 19,100 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 161,822 shares. The stock had previously closed at $0.18.
Vyant Bio Trading Up 7.8 %
The stock has a 50 day moving average of $0.19 and a two-hundred day moving average of $0.19. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.04.
Vyant Bio Company Profile
Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).
Recommended Stories
- Five stocks we like better than Vyant Bio
- 3 Dividend Kings To Consider
- 3 Mid-Cap Medical Stocks Outperforming the Market
- What does consumer price index measure?
- The Top-Ranked Insider Buys From April by Market Cap
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.
